Terns' late-stage assets target CML & obesity with key data in Q4 2025. Explore their potential in massive markets. Click ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

Cantor Fitzgerald cut Eli Lilly’s FY2025 earnings forecast from $21.91 to $21.76 per share. Eli Lilly reported $3.34 per ...

Shares of Eli Lilly & Co. LLY rose 1.19% to $786.92 Wednesday, on what proved to be an all-around great trading session for ...

UBS has reiterated its Buy rating and $1,050 price target on LLY stock, highlighting the company’s growing dominance in the ...

Eli Lilly and Company (NYSE:LLY) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On June 22, Eli Lilly and ...

Eli Lilly and Johnson & Johnson, PPH’s largest holdings, are facing unique challenges, impacting the ETF’s overall ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...